Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 9/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | PPIA | P62937 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13289651 | 0.89 | HDAC1 (0.53) | HDAC1MCHR1HDAC4MEF2DMGLL | |
| SCHEMBL2748541 | 0.80 | HDAC1 (0.48) | HDAC1MCHR1HDAC4MEF2D | |
| SCHEMBL13991977 | 0.80 | HDAC1 (0.40) | HDAC1MCHR1HDAC4MEF2D | |
| SCHEMBL5018180 | 0.76 | HDAC1 (0.42) | HDAC1MCHR1HDAC4MEF2D | |
| SCHEMBL5024166 | 0.76 | MCHR1 (0.51) | HDAC1MCHR1HDAC4PABPC1 | |
| SCHEMBL12341539 | 0.74 | HDAC4 (0.43) | HDAC1MCHR1HDAC4MEF2D | |
| SCHEMBL10084241 | 0.74 | HDAC4 (0.43) | HDAC1MCHR1HDAC4MEF2D | |
| SCHEMBL13289652 | 0.74 | HDAC1 (0.43) | HDAC1MCHR1HDAC4MEF2D | |
| SCHEMBL1244241 | 0.73 | HDAC1 (0.53) | HDAC1HDAC4MEF2DPABPC1NOTUM | |
| SCHEMBL10420281 | 0.72 | HDAC1 (0.73) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318957-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318957-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | HDAC1 852/4885MCHR1 4499/4885HDAC4 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.